PFD ( DrugBank: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
| 117 | Syringomyelia | 1 |
| 298 | Hereditary pancreatitis | 2 |
51. Scleroderma
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03221257 (ClinicalTrials.gov) | November 28, 2017 | 12/7/2017 | Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate | Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease | Scleroderma, Systemic;Interstitial Lung Disease | Drug: Pirfenidone (PFD);Drug: Placebo (Plac);Drug: Mycophenolate Mofetil (MMF) | Michael Roth | University of Michigan;Genentech, Inc.;University of California, Los Angeles | Active, not recruiting | 18 Years | N/A | All | 51 | Phase 2 | United States |
117. Syringomyelia
Clinical trials : 3 / Drugs : 5 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000039678 | 2021-02-01 | 2020-11-05 | Evaluation of Posterior Fossa Decompression (PFD) without or with Cerebellar Tonsil Thermocoagulation (PFDCT) for Arnold-Chiari Malformation Type I with Syringomyelia: a ramdomised controlled trial | Evaluation of Posterior Fossa Decompression (PFD) without or with Cerebellar Tonsil Thermocoagulation (PFDCT) for Arnold-Chiari Malformation Type I with Syringomyelia: a ramdomised controlled trial | Arnold-Chiari Malformation Type I with Syringomyelia | A Group:Posterior Fossa Decompression;B Group:Posterior Fossa Decompression (PFD) with Cerebellar tonsil Thermocoagulation (PFDCT); | Fujian Medical University Union Hospital | NULL | Recruiting | 18 | 65 | Both | A Group:70;B Group:70; | China |
298. Hereditary pancreatitis
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000028150 | 2017/07/10 | 10/07/2017 | Analysis of apolipoprotein A2 isoform as a novel pancreatic exocrine marker | Healthy volunteers, patients with chronic pancreatitis, patients with chronic hepatitis | Blood test and PFD test | Yokohama City University | NULL | Recruiting | 20years-old | 75years-old | Male and Female | 200 | Not selected | Japan | |
| 2 | JPRN-UMIN000008340 | 2012/08/01 | 04/07/2012 | pancreatic exocrine function with non-contrast MRI:Visualization by Means of MRCP with Spatially Selective Inversion-Recovery Pulse | Chronic pancreatitis | MRCP/PFD test MRCP | the Department of Diagnostic Radiology Kawasaki Medical School | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 40 | Not selected | Japan |